The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Noden Pharma DACEU/1/07/405/11-20,31-40

Main Information

Trade NameRasilez
Active SubstancesAliskiren hemifumarate
Dosage FormFilm-coated tablet
Licence HolderNoden Pharma DAC
Licence NumberEU/1/07/405/11-20,31-40

Group Information

ATC CodeC09XA Renin-inhibitors
C09XA02 aliskiren


License statusAuthorised
Licence Issued22/08/2007
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back